Clinical trials: Cognitive Deficits
- Condition Cognitive Deficits
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Healthy
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers
- Trial name
- NCT02228395
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Cognitive Decline, Focus Deficit
Effects of Auri Super Mushroom Daily Gummies on Cognitive Health
This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks.
- Trial name
- NCT07198399
- Testing
- Auri Super Mushroom Daily Gummies
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Auri Nutrition
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Huntington Disease
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD).
- Trial name
- BioDigit HD-02 (NCT07315984)
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BioSensics
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Healthy, Cognitive Impairment
Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology
The study is designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical assessments and BNA scores.
- Conditions
- Healthy, Cognitive Impairment, Neurological Disorder
- Trial name
- NCT03699514
- Testing
- Brain Network Activation (BNA™) technology
- Where
- 4 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Alzheimer's Disease
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
1. To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association…
- Trial name
- NCT07752784
- Testing
- [18F]-APN-1607
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02342041
- Testing
- SUVN-G3031
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT05466422
- Testing
- MK-2214
- Where
- 12 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Memory Deficits, Cognitive Change
An Exploratory Investigation of a Supplement to Promote Brain Health
Providing a combination of synergistic dietary supplements, such as vitamins B6, B12, and folate, as well as curcumin, lemon balm, and American ginseng is hypothesized to promote brain health and aid with brain fog, mental…
- Conditions
- Memory Deficits, Cognitive Change, Stress
- Trial name
- NCT05520424
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Parable
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers
This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
- Trial name
- NCT01959594
- Testing
- 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mild Cognitive Impairment
Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment
This study is designed to evaluate the preliminary effectiveness and safety of a digitally based multidomain intervention in patients with MCI.
- Trial name
- NCT05059353
- Testing
- Digitally based multidomain intervention
- Where
- Singapore
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Neuroglee Therapeutics
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Risk Behavior, Cognitive Decline
Multidomain Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help middle-aged to older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors…
- Trial name
- NCT05141578
- Testing
- Luci Coach Assisted Intervention
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- LuciLab
Alzheimer Disease, Dementia
Reducing Dementia Risk With Digital Health Coaching
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- DC-MARVEL (NCT04559789)
- Testing
- MindMate + Health Coaching, Health Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neurotrack Technologies, Inc.